Samsara R&D increased by 3.8% to $89.52M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.2%, from $73.28M to $89.52M. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 13.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.53M | $25.45M | $29.69M | $126.46M | $40.99M | $41.85M | $49.97M | $54.60M | $60.37M | $63.97M | $60.82M | $73.43M | $72.97M | $76.48M | $76.99M | $73.28M | $83.24M | $85.61M | $86.22M | $89.52M |
| QoQ Change | — | +8.2% | +16.6% | +326.0% | -67.6% | +2.1% | +19.4% | +9.3% | +10.6% | +6.0% | -4.9% | +20.7% | -0.6% | +4.8% | +0.7% | -4.8% | +13.6% | +2.8% | +0.7% | +3.8% |
| YoY Change | — | — | — | — | +74.2% | +64.4% | +68.3% | -56.8% | +47.3% | +52.9% | +21.7% | +34.5% | +20.9% | +19.6% | +26.6% | -0.2% | +14.1% | +11.9% | +12.0% | +22.2% |